EXEL vs. SYNH, PRAH, CRL, MEDP, NRC, BMRN, INCY, UTHR, NBIX, and EXAS
Should you be buying Exelixis stock or one of its competitors? The main competitors of Exelixis include Syneos Health (SYNH), PRA Health Sciences (PRAH), Charles River Laboratories International (CRL), Medpace (MEDP), National Research (NRC), BioMarin Pharmaceutical (BMRN), Incyte (INCY), United Therapeutics (UTHR), Neurocrine Biosciences (NBIX), and Exact Sciences (EXAS).
Syneos Health (NASDAQ:SYNH) and Exelixis (NASDAQ:EXEL) are both mid-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, community ranking, profitability, earnings, risk, analyst recommendations and media sentiment.
91.2% of Syneos Health shares are owned by institutional investors. Comparatively, 85.3% of Exelixis shares are owned by institutional investors. 0.3% of Syneos Health shares are owned by company insiders. Comparatively, 2.9% of Exelixis shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Exelixis has a consensus price target of $26.13, suggesting a potential upside of 11.69%. Given Syneos Health's higher probable upside, analysts plainly believe Exelixis is more favorable than Syneos Health.
Exelixis has a net margin of 11.10% compared to Exelixis' net margin of 1.31%. Syneos Health's return on equity of 8.85% beat Exelixis' return on equity.
In the previous week, Exelixis had 22 more articles in the media than Syneos Health. MarketBeat recorded 22 mentions for Exelixis and 0 mentions for Syneos Health. Syneos Health's average media sentiment score of 0.94 beat Exelixis' score of 0.00 indicating that Exelixis is being referred to more favorably in the news media.
Syneos Health has higher revenue and earnings than Exelixis. Exelixis is trading at a lower price-to-earnings ratio than Syneos Health, indicating that it is currently the more affordable of the two stocks.
Exelixis received 34 more outperform votes than Syneos Health when rated by MarketBeat users. Likewise, 68.27% of users gave Exelixis an outperform vote while only 63.98% of users gave Syneos Health an outperform vote.
Syneos Health has a beta of 1.58, suggesting that its stock price is 58% more volatile than the S&P 500. Comparatively, Exelixis has a beta of 0.54, suggesting that its stock price is 46% less volatile than the S&P 500.
Summary
Exelixis beats Syneos Health on 11 of the 17 factors compared between the two stocks.
Get Exelixis News Delivered to You Automatically
Sign up to receive the latest news and ratings for EXEL and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding EXEL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Exelixis Competitors List
Related Companies and Tools
Free EXEL Stock Alerts